STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPP
  4. [EFFECT] Rapport Therapeutics, Inc. SEC Filing

[EFFECT] Rapport Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 9, 2025 4:01 P.M.
Form: S-3
CIK: 0002012593
Company Name: Rapport Therapeutics, Inc.
File Number: 333-288444

Source: View Original Filing on SEC EDGAR

Stock RAPP logo
Rapport Therapeutics Inc

NASDAQ:RAPP

RAPP Rankings

#2537 Ranked by Market Cap
N/A Ranked by Dividends

RAPP Latest News

Jan 7, 2026
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
Dec 18, 2025
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Dec 5, 2025
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Nov 25, 2025
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Nov 6, 2025
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

RAPP Latest SEC Filings

Feb 17, 2026
[SCHEDULE 13G/A] Rapport Therapeutics, Inc. Amended Passive Investment Disclosure
Feb 4, 2026
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity
Feb 4, 2026
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity
Feb 4, 2026
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity
Feb 4, 2026
[Form 4] Rapport Therapeutics, Inc. Insider Trading Activity

RAPP Stock Data

1.39B
45.04M
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON